leuprorelin
Commercial- Indications
- Prostate cancer
Company intelligence / Profile preview
TAP Pharmaceuticals
Lake Forest, Illinois, USAtappharma.ch ↗
- Ownership
- Private
- Employees
- ~320
- Development stage
- Commercial
01
Overview
TAP marketed two blockbuster drugs: lansoprazole (Prevacid), a proton-pump inhibitor for ulcers and acid reflux, and leuprorelin acetate depot injection (Lupron Depot), a leading prostate cancer drug. Both had worldwide sales exceeding $1 billion at peak[1][2].
- Therapeutic areas
- OncologyGastroenterology
- Modalities
- Small molecules (e.g., lansoprazole/Prevacid, leuprorelin/Lupron)
- Industry
- Pharma
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Joint venture partnership between Abbott Laboratories and Takeda Pharmaceutical Company from 1977 until dissolution in 2008[1][4].
Beyond the preview
Go deeper on TAP Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAP Pharmaceuticals.